Showing results (11-20 of 81) with videos related to
Sort By:
Pageof 9
The FEBS Journal|April 24, 2025
Transcription-coupled repair: tangled up in convoluted repairDiana A Llerena Schiffmacher, Yun Jin Pai, Alex Pines, et al.Therapeutic Drug Monitoring|April 1, 1992
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotypeA Llerena, C Alm, M L Dahl, et al.Acta Psychiatrica Scandinavica|January 1, 1993
Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6A Llerena, G Edman, J Cobaleda, et al.Clinical Pharmacology and Therapeutics|December 1, 1993
Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agentsA LLerena, A G Herraíz, J Cobaleda, et al.The American Journal of the Medical Sciences|January 1, 2000
Hypercalcemia associated with infection by Cryptococcus neoformans and Coccidioides immitisM Y Ali, K V Gopal, L A Llerena, et al.The Annals of Pharmacotherapy|February 17, 2000
Syndrome of inappropriate antidiuretic hormone secretion associated with lisinoprilZ H Shaikh, H C Taylor, P V Maroo, et al.Current Drug Targets|December 16, 2006
Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugsP Dorado, R Berecz, E M Peñas-Lledó, et al.Revista De Enfermeria (Barcelona, Spain)|February 28, 2001
[Poisoning by organophosphate insecticides. Epidemiology and prevention]M J Norberto Gamero, M Martínez Alvarez, S Postigo Mota, et al.European Journal of Clinical Pharmacology|June 13, 2008
Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteersP Dorado, I Cavaco, M C Cáceres, et al.Therapeutic Drug Monitoring|January 22, 2002
Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypesA LLerena, R Berecz, A de la Rubia, et al.Pageof 9